| Dr Sean Matthew Blaydon, MD | |
|
3705 Medical Pkwy, Suite 120, Austin, TX 78705-1019 | |
| (512) 458-2141 | |
| (512) 458-4824 |
| Full Name | Dr Sean Matthew Blaydon |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 35 Years |
| Location | 3705 Medical Pkwy, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730170622 | NPI | - | NPPES |
| 047566701 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | K4374 (Texas) | Secondary |
| 207WX0200X | Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery | K4374 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Oculoplastic Consultants Llp | 3173594249 | 11 |
News Archive
The Minister of State at the Department of Health and Children, Ireland, Mr. Tim O´Malley, T.D. today (26th April 2004) launched the final report of the Empowerment of Nurses and Midwives Steering Group - An Agenda for Change.
Repros Therapeutics Inc. today announced that the Company has received the FDA's version of the minutes of the Type C meeting held on January 25, 2010. The minutes confirmed the Company's interpretation of the points the Agency made during the meeting. In correspondence from the FDA prior to the meeting the Agency noted that they could not currently agree with the Company's stated indication for the use of Androxal® in the treatment of secondary hypogonadism in men wishing to preserve fertility.
Translational medical research has been given a major boost with the introduction of a new biobanking resource at Griffith University's Gold Coast campus.
DNA nanotechnology - the research field using DNA molecules as building material - has developed rapidly during recent years and enabled the construction of increasingly complex nanostructures.
› Verified 6 days ago
| Entity Name | Texas Oculoplastic Consultants Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942270103 PECOS PAC ID: 3173594249 Enrollment ID: O20040803000574 |
News Archive
The Minister of State at the Department of Health and Children, Ireland, Mr. Tim O´Malley, T.D. today (26th April 2004) launched the final report of the Empowerment of Nurses and Midwives Steering Group - An Agenda for Change.
Repros Therapeutics Inc. today announced that the Company has received the FDA's version of the minutes of the Type C meeting held on January 25, 2010. The minutes confirmed the Company's interpretation of the points the Agency made during the meeting. In correspondence from the FDA prior to the meeting the Agency noted that they could not currently agree with the Company's stated indication for the use of Androxal® in the treatment of secondary hypogonadism in men wishing to preserve fertility.
Translational medical research has been given a major boost with the introduction of a new biobanking resource at Griffith University's Gold Coast campus.
DNA nanotechnology - the research field using DNA molecules as building material - has developed rapidly during recent years and enabled the construction of increasingly complex nanostructures.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean Matthew Blaydon, MD 3705 Medical Pkwy, Suite 120, Austin, TX 78705-1019 Ph: (512) 458-2141 | Dr Sean Matthew Blaydon, MD 3705 Medical Pkwy, Suite 120, Austin, TX 78705-1019 Ph: (512) 458-2141 |
News Archive
The Minister of State at the Department of Health and Children, Ireland, Mr. Tim O´Malley, T.D. today (26th April 2004) launched the final report of the Empowerment of Nurses and Midwives Steering Group - An Agenda for Change.
Repros Therapeutics Inc. today announced that the Company has received the FDA's version of the minutes of the Type C meeting held on January 25, 2010. The minutes confirmed the Company's interpretation of the points the Agency made during the meeting. In correspondence from the FDA prior to the meeting the Agency noted that they could not currently agree with the Company's stated indication for the use of Androxal® in the treatment of secondary hypogonadism in men wishing to preserve fertility.
Translational medical research has been given a major boost with the introduction of a new biobanking resource at Griffith University's Gold Coast campus.
DNA nanotechnology - the research field using DNA molecules as building material - has developed rapidly during recent years and enabled the construction of increasingly complex nanostructures.
› Verified 6 days ago
Dr. Kristen Michelle Hawthorne, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Saradha Chexal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy Ste 460, Austin, TX 78705 Phone: 512-454-5851 | |
Dr. John David Fisher, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2901 Montopolis Dr, Austin, TX 78741 Phone: 512-389-6571 Fax: 512-389-6511 | |
Dr. Clio Armitage Harper Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 W 38th St, Suite 200, Austin, TX 78705 Phone: 512-451-0103 Fax: 512-451-2741 | |
Dr. Nadja Ivette Torres, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Fuad Makkouk, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9707 Anderson Mill Rd Ste 230, Austin, TX 78750 Phone: 512-693-9363 | |
Irina Volosko, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3410 Far West Blvd Ste 140, Austin, TX 78731 Phone: 512-427-1107 Fax: 512-427-1207 |